Ken Griffin Arbutus Biopharma Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $95,472 - $139,536	30,600 Added 129.11%	54,300 $209,000
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $174,888 - $251,922	-69,400 Reduced 74.54%	23,700 $73,000
Q1 2024 May 15, 2024	SELL	$2.26 - $2.92 $35,708 - $46,136	-15,800 Reduced 14.51%	93,100 $240,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $21,463 - $32,258	12,700 Added 13.2%	108,900 $272,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $25,270 - $30,191	-13,300 Reduced 12.15%	96,200 $195,000
Q2 2023 Aug 14, 2023	SELL	$2.24 - $3.06 $124,992 - $170,748	-55,800 Reduced 33.76%	109,500 $251,000
Q1 2023 May 15, 2023	SELL	$2.23 - $3.1 $150,971 - $209,870	-67,700 Reduced 29.06%	165,300 $500,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $27,122 - $40,470	14,200 Added 6.49%	233,000 $542,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $8,836 - $13,536	4,700 Added 2.2%	218,800 $418,000

156

99.6M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $520M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.